belatacept
Sign in to saveAlso known as LEA029, BMS-224818, Nujolix, LEA29Y, CD152 antigen, CTLA4-Ig, LEA 29Y, BMS224818
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant
Wikidata facts
Show 2 more facts
- World Health Organisation international non-proprietary name
- belatacept
- defined daily dose
- 12.5
via Wikidata · CC0
~1 min read
Article
2 sectionsContents
- References
- External links
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.
Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.